Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA 2016; 66:7-30; PMID:26742998; http://dx.doi.org/10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Awan FT, Byrd JC. New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res 2014; 20:5869-74; PMID:25294898; http://dx.doi.org/10.1158/1078-0432.CCR-14-1889
   PubMed Web of Science ®Google Scholar
• Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008; 141:607-14; PMID:18384436; http://dx.doi.org/10.1111/j.1365-2141.2008.07070.x
   PubMed Web of Science ®Google Scholar
• Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32:632-46; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
   PubMed Web of Science ®Google Scholar
• Arlettaz L, Villard J, de Rham C, Degermann S, Chapuis B, Huard B, Roosnek E. Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR αβ lymphocytes. Eur J Immunol 2004; 34:3456-64; PMID:15517612; http://dx.doi.org/10.1002/eji.200425210
   PubMed Web of Science ®Google Scholar
• Jabri B, Selby JM, Negulescu H, Lee L, Roberts AI, Beavis A, Lopez-Botet M, Ebert EC, Winchester RJ. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 2002; 17:487-99; PMID:12387742; http://dx.doi.org/10.1016/S1074-7613(02)00427-2
   PubMed Web of Science ®Google Scholar
• Jabri B, De Serre NPM, Cellier C, Evans K, Gache C, Carvalho C, Mougenot JF, Allez M et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000; 118:867-79; PMID:10784586; http://dx.doi.org/10.1016/S0016-5085(00)70173-9
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122:2539-49; PMID:23886836; http://dx.doi.org/10.1182/blood-2013-06-507947
   PubMed Web of Science ®Google Scholar
• Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9; PMID:9486650; http://dx.doi.org/10.1038/35869
   PubMed Web of Science ®Google Scholar
• Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187:813-8; PMID:9480992; http://dx.doi.org/10.1084/jem.187.5.813
   PubMed Web of Science ®Google Scholar
• Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998; 95:5199-204; PMID:9560253; http://dx.doi.org/10.1073/pnas.95.9.5199
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008; 111:5446-56; PMID:18216293; http://dx.doi.org/10.1182/blood-2007-06-093906
   PubMed Web of Science ®Google Scholar
• Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist; 18(1):50-60; http://dx.doi.org/10.1214/aoms/1177730491
   Google Scholar
• Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer-Verlag New York, 2000; 570:1; http://dx.doi.org/10.1007/978-1-4419-0300-6
   Google Scholar
• Hsu J. Multiple comparisons: theory and methods. CRC Press Boca Raton, FL, 1996; http://dx.doi.org/10.1007/978-1-4899-7180-7
   Google Scholar
• Wieten L, Mahaweni NM, Voorter CEM, Bos GMJ, Tilanus MGJ. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 2014; 84:523-35; PMID:25413103; http://dx.doi.org/10.1111/tan.12478
   PubMed Web of Science ®Google Scholar
• Gustafson KS, Ginder GD. Interferon-γ induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1α to a distinct interferon-γ-responsive element. J Biol Chem 1996; 271:20035-46; PMID:8702722; http://dx.doi.org/10.1074/jbc.271.33.20035
   PubMed Web of Science ®Google Scholar
• Marusina AI, Kim D-K, Lieto LD, Borrego F, Coligan JE. GATA-3 is an important transcription factor for regulating human NKG2A gene expression. J Immunol 2005; 174:2152-9; PMID:15699146; http://dx.doi.org/10.4049/jimmunol.174.4.2152
   PubMed Web of Science ®Google Scholar
• Ziegler H-W, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27:321-7; PMID:6169660; http://dx.doi.org/10.1002/ijc.2910270310
   PubMed Web of Science ®Google Scholar
• Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305-9; PMID:6607080
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010; 116:3705-14; PMID:20610811; http://dx.doi.org/10.1182/blood-2010-04-001230
   PubMed Web of Science ®Google Scholar
• Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V et al. Primary B-CLL resistance to NK Cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32:632-46; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
   PubMed Web of Science ®Google Scholar
• Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 2005; 5:459-71; PMID:15928678; http://dx.doi.org/10.1038/nri1635
   PubMed Web of Science ®Google Scholar
• Koller BH, Geraghty DE, Shimizu Y, DeMars R, Orr HT. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol 1988; 141:897-904; PMID:3260916
   PubMed Web of Science ®Google Scholar
• Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177:213-8; PMID:7678114; http://dx.doi.org/10.1084/jem.177.1.213
   PubMed Web of Science ®Google Scholar
• Carretero M, Palmieri G, Llano M, Tullio V, Santoni A, Geraghty DE, López-Botet M. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. Eur J Immunol 1998; 28:1280-91; PMID:9565368; http://dx.doi.org/10.1002/(SICI)1521-4141(199804)28:04%3c1280::AID-IMMU1280%3e3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Palmieri G, Tullio V, Zingoni A, Piccoli M, Frati L, Lopez-Botet M, Santoni A. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J Immunol 1999; 162:7181-8; PMID:10358164
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang J, Sun R, Feng J, Wei H, Tian Z. Opposing effect of IFNγ and IFNα on expression of NKG2 receptors: Negative regulation of IFNγ on NK cells. Int Immuno Pharmacol 2005; 5:1057-67; PMID:15829421; http://dx.doi.org/10.1016/j.intimp.2005.02.003
   PubMed Web of Science ®Google Scholar
• Nguyen S, Dhedin N, Vernant J-P, Kuentz M, Jijakli AA, Rouas-Freiss N, Carosella ED, Boudifa A, Debré P, Vieillard V. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105:4135-42; PMID:15687235; http://dx.doi.org/10.1182/blood-2004-10-4113
   PubMed Web of Science ®Google Scholar
• Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol 2015; 67:171-82; PMID:25900877; http://dx.doi.org/10.1016/j.molimm.2015.03.255
   PubMed Web of Science ®Google Scholar
• Gunturi A, Berg RE, Crossley E, Murray S, Forman J. The role of TCR stimulation and TGF-β in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur J Immunol 2005; 35:766-75; PMID:15714583; http://dx.doi.org/10.1002/eji.200425735
   PubMed Web of Science ®Google Scholar
• Seymour L, Tinker A, Hirte H, Wagtmann N, Dodion P. O3.2Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Annals Oncol 2015; 26:ii3; http://dx.doi.org/10.1093/annonc/mdv081.2
   Google Scholar